Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 52002XC0726(02)

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 June to 15 July 2002 (Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council)

OJ C 178, 26.7.2002, p. 8–19 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)

52002XC0726(02)

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 June to 15 July 2002 (Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council)

Official Journal C 178 , 26/07/2002 P. 0008 - 0019


Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 June to 15 July 2002

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council(1) or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council(2))

(2002/C 178/05)

- Issuing, maintenance or modification of a national marketing authorisation

>TABLE>

- Lift of suspension of a marketing authorisation

>TABLE>

(1) OJ L 311, 28.11.2001, p. 67.

(2) OJ L 311, 28.11.2001, p. 1.

ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES

>TABLE>

ANNEX II

LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, STRENGTHS, PHARMACEUTICAL FORMS, ROUTE OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES

SERTINDOLE-CONTAINING MEDICINAL PRODUCTS WITH MARKETING AUTHORISATION IN THE EUROPEAN UNION

>TABLE>

Top
  翻译: